[Action of an anti-viral on the Australia antigen in patients with hepatitis A virus and in healthy carriers].
Patients with positive serum HBAg reactions were treated with Viramid (1-beta-D-ribofuranozyl-1, 2, 4-triazol-3-carboxamide) a new anti-viral drug. Of the patients involved in this study, 5 had chronic hepatitis or prolonged hepatitis and 12 were healthy HBAg carriers. Results obtained suggest that the drug had some action on serum HBAg titres with a decrease or negativation of HBAg serum titres in peripheric blood, the evaluation of which was immediately seen by employing the counterimmune electrophoresis technique.
D000293:Adolescent; D000328:Adult; D000998:Antiviral Agents / Q000494:pharmacology* / Q000627:therapeutic use; D002214:Capsules; D002353:Carrier State; D002648:Child; D004341:Drug Evaluation; D005260:Female; D006506:Hepatitis A / Q000188:drug therapy*; D006514:Hepatitis B Surface Antigens / Q000032:analysis; D006801:Humans; D008297:Male; D008875:Middle Aged; D012254:Ribavirin / Q000494:pharmacology* / Q000627:therapeutic use; D012263:Ribonucleosides / Q000494:pharmacology*
D000998:Antiviral Agents; D002214:Capsules; D006514:Hepatitis B Surface Antigens; D012263:Ribonucleosides; D012254:Ribavirin
Acao de uma nova droga anti-viral sobre o antigeno australia em pacientes com hepatite A virus e em portadores saos.